Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies

INTRODUCTION: The apolipoprotein A1 (apoA1) remnant ratio has been identified as an independent cardiovascular (CV) risk factor. Higher apoA1 remnant ratios may predict lower CV risk in some patients. This analysis aimed to evaluate the effects of evolocumab on the change from baseline in the apoA1...

Descripción completa

Detalles Bibliográficos
Autores principales: May, Heidi T., Muhlestein, Joseph B., Ma, Yuhui, López, J. Antonio G., Coll, Blai, Nelson, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525215/
https://www.ncbi.nlm.nih.gov/pubmed/30852766
http://dx.doi.org/10.1007/s40119-019-0133-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525215/
https://www.ncbi.nlm.nih.gov/pubmed/30852766
http://dx.doi.org/10.1007/s40119-019-0133-6

Ejemplares similares